News
A new genetic test, based on data from more than five million people, can identify people at risk of severe obesity. The test can be performed on children before their genetic risk starts to shape ...
Amgen's expanding rare disease and biosimilar portfolios, coupled with growth potential and dividend history make AMGN stock ...
Monday said that the European Patent Office (EPO) has issued a notice of allowance for a composition of matter patent covering its drug candidate LP-284.
Much of the public distrust stems from false information around messenger RNA (mRNA) vaccines for COVID-19, even though they ...
4d
Zacks Investment Research on MSNMDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing Rights
Madrigal Pharmaceuticals MDGL shares soared 10.9% on Wednesday. The uptrend was observed after the U.S. Patent and Trademark ...
Reports say Novo Nordisk may have inadvertently let generics of its GLP-1 drug semaglutide for diabetes and obesity launch in Canada early next year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results